Monopar Therapeutics (MNPR) Liabilities and Shareholders Equity (2016 - 2025)

Monopar Therapeutics (MNPR) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $140.7 million in Q4 2025.

• For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 133.4% year-over-year to $140.7 million; the trailing twelve-month figure through Dec 2025 stood at $393.9 million (up 377.69% YoY), and the FY2025 full-year result was $140.7 million, up 133.4% from the prior year.
• Liabilities and Shareholders Equity eased to $140.7 million in Q4 2025, from $144.2 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $144.2 million in Q3 2025 to a low of $6.1 million in Q3 2024.
• A 5-year average of $33.5 million and a median of $17.4 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slumped 44.47% in 2023 and soared 2275.71% in 2025, its largest moves.
• Tracing MNPR's Liabilities and Shareholders Equity over 5 years: stood at $20.5 million in 2021, then plunged by 35.55% to $13.2 million in 2022, then slumped by 44.47% to $7.3 million in 2023, then surged by 720.83% to $60.3 million in 2024, then jumped by 133.4% to $140.7 million in 2025.
• Business Quant data shows MNPR's Liabilities and Shareholders Equity at $140.7 million in Q4 2025, $144.2 million in Q3 2025, and $53.9 million in Q2 2025.